Worth reading
74In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
40
Millions of yen (year-on-year increase in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ended December 202513 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥4,423 million+1.6%
Operating profit¥1,093 million+3.8%
Ordinary income¥1,059 million-6.5%
Net income¥476 million-38.9%
Gross Profit Margin62.1%
Operating profit margin24.7%
Selling, general and administrative expenses¥1,655 million
Results for the three months of the current quarter
Net Sales
¥4,423 million
Operating profit
¥1,093 million
Ordinary income
¥1,059 million
Net income
¥476 million
Full-year earnings forecast
Net Sales
¥20,000 million
Operating profit
¥5,000 million
Ordinary income
¥5,100 million
Net income
¥3,600 million
Earnings per share
¥192.26
Annual Dividend
¥55
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales22.1%
Operating profit21.9%
Ordinary income20.8%
Net income13.2%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Adhesion promoters278
Etchants25
Other Chemicals-22
Machinery sales-342
Materials sales91
Other sales6
Foreign exchange impact32
Operating profit
Chemical product sales and volume98
Chemical product gross profit margin111
Machinery sales-75
Machinery gross profit margin0
Materials and other sales43
Materials and other gross profit margin0
Foreign exchange effects (gross profit)21
Selling, general and administrative expenses-149
Foreign exchange effects (SG&A expenses)-9
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
NTD¥4.76
RMB¥21.08
HKD¥19.48
THB¥4.22
EUR¥164.84
USD¥152.33
Business Environment半導体市況の回復基調、PKG基板の増加、超高密度化・超高周波化
New initiatives
- 北九州工場（仮称）の新設。最大生産能力2,500t/月、2026年12月稼働予定
- APシリーズなど化学密着技術の展開
- PKG基板関連で得た技術をデータセンター等向けPCB基板へ展開
Key KPIsA metric the company considers important as a management benchmark.
- 薬品出荷量10,247 ton+4.0%
- Overseas revenue ratio65.5%
- 国内代理店経由の海外顧客を含む海外売上高比率80.4%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Shipment volume
10,247 ton+4.0%
Segment results
品種別売上高
Chemicals
¥4,237 million+8.0%
Machinery
¥49 million
Materials
¥128 million
Other
¥8 million
Regional sales
Japan
¥1,594 million
Taiwan
¥860 million
China
¥1,370 million
Europe
¥400 million
Thailand
¥197 million
Medium-term management plan targets
Plan2030年ビジョン中期経営計画Phase2（2025〜2027年）
Shareholder Returns1株当たり年間配当金の維持・成長、連結配当性向30％目標
ROEAt least 10%
Financial targets
ROE targetAt least 10%
Actual ROE1.8%
Number of employees
Consolidated480 People
Standalone277 People
Capital expenditures
¥2,097 million2025年12月期予想
Annual Dividend
¥55 per share
Payout ratio
30% target
Acquisition of treasury shares
PolicyTo be conducted flexibly as appropriate
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ended December 2025 |
| Net Sales | ¥4,423 million (YoY +1.6%) |
| Operating profit | ¥1,093 million (YoY +3.8%) |
| Ordinary income | ¥1,059 million (YoY -6.5%) |
| Net income | ¥476 million (YoY -38.9%) |
| Gross Profit Margin | 62.1% |
| Operating profit margin | 24.7% |
| Selling, general and administrative expenses | ¥1,655 million |
| Results for the three months of the current quarter | Net Sales ¥4,423 million / Operating profit ¥1,093 million / Ordinary income ¥1,059 million / Net income ¥476 million |
| Full-year earnings forecast | Net Sales ¥20,000 million / Operating profit ¥5,000 million / Ordinary income ¥5,100 million / Net income ¥3,600 million / Earnings per share ¥192.26 / Annual Dividend ¥55 |
| Progress against full-year forecast | Net Sales 22.1% / Operating profit 21.9% / Ordinary income 20.8% / Net income 13.2% |
| Segment results | 品種別売上高 Chemicals ¥4,237 million (YoY +8.0%) / Machinery ¥49 million / Materials ¥128 million / Other ¥8 million / Regional sales Japan ¥1,594 million / Taiwan ¥860 million / China ¥1,370 million / Europe ¥400 million / Thailand ¥197 million |
| Breakdown of Factors Affecting the Change | Net Sales Adhesion promoters 278 / Etchants 25 / Other Chemicals -22 / Machinery sales -342 / Materials sales 91 / Other sales 6 / Foreign exchange impact 32 / Operating profit Chemical product sales and volume 98 / Chemical product gross profit margin 111 / Machinery sales -75 / Machinery gross profit margin 0 / Materials and other sales 43 / Materials and other gross profit margin 0 / Foreign exchange effects (gross profit) 21 / Selling, general and administrative expenses -149 / Foreign exchange effects (SG&A expenses) -9 |
| Key KPIs | 薬品出荷量 10,247 ton (YoY +4.0%), Overseas revenue ratio 65.5%, 国内代理店経由の海外顧客を含む海外売上高比率 80.4% |
| Unit price and quantity metrics | Shipment volume 10,247 ton (YoY +4.0%) / Unit price Not disclosed |
| Number of employees | Consolidated 480 People / Standalone 277 People / Change during the period Not disclosed / Hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Exchange rate NTD ¥4.76 / RMB ¥21.08 / HKD ¥19.48 / THB ¥4.22 / EUR ¥164.84 / USD ¥152.33 / Business Environment 半導体市況の回復基調、PKG基板の増加、超高密度化・超高周波化 |
| Medium-term management plan targets | Plan 2030年ビジョン中期経営計画Phase2（2025〜2027年） / Shareholder Returns 1株当たり年間配当金の維持・成長、連結配当性向30％目標 / ROE At least 10% |
| Financial targets | ROE target At least 10% / Actual ROE 1.8% |
| Annual Dividend | ¥55 per share |
| Payout ratio | 30% target |
| Acquisition of treasury shares | Policy To be conducted flexibly as appropriate / Buyback limit Not disclosed |
| Capital expenditures | 2,097 百万円（2025年12月期予想） |
| New initiatives | 北九州工場（仮称）の新設。最大生産能力2,500t/月、2026年12月稼働予定, APシリーズなど化学密着技術の展開, PKG基板関連で得た技術をデータセンター等向けPCB基板へ展開 |
Items this document does not state (6)
Self-assessment against the planNumber of stores and locationsRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、薬品売上・数量、薬品粗利益率、資材売上、為替の影響が営業利益の増加要因となった一方、機械売上、販管費、為替の影響（粗利）が減少要因となったと説明している。売上高については、密着向上剤、エッチング剤、機械売上、資材売上、為替の影響などを増減要因として示している。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.